Status:
NOT_YET_RECRUITING
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
Lead Sponsor:
Badr University
Conditions:
Non-alcoholic Fatty Liver Disease NAFLD
Non-alcoholic Steatohepatitis NASH
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to assess the efficacy of Empagliflozin versus Statins as monotherapy and polytherapy in non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis. Does d...
Detailed Description
NAFLD is a growing global health problem linked with metabolic issues like obesity, diabetes, and insulin resistance. It ranges from simple liver fat accumulation to NASH, involving inflammation and l...
Eligibility Criteria
Inclusion
- Adult
- Obese
- Hyperlipidemic
- Diabetic patients
- Diagnosed with non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis
Exclusion
- Pregnant women
- Breast feeding women
- Diabetic patients with ketoacidosis
- Hyperlipidemic patients with cardiovascular dysfunction
- Patients with NAFLD or NASH induced hepatocellular carcinoma
- Hyperlipidemic obese diabetic patients diagnosed with NAFLD or NASH who will refuse to sign the informed consent
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT07180745
Start Date
November 1 2025
End Date
March 1 2026
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Teaching hospital of Beni Suef University
Banī Suwayf, Egypt, 62727